DL-TBOA ammonium 

DL-TBOA ammonium is a potent non-transportable inhibitor of excitatory amino acid transporters with IC₅₀s of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter-1 (EAAT1), EAAT2 and EAAT3, respectively. DL-TBOA ammonium inhibits the uptake of [¹⁴C]glutamate in COS-1 cells expressing the human EAAT1 and EAAT2 with K_i valuesof 42 μM and 5.7 μM, respectively. DL-TBOA ammonium blocks EAAT4 and EAAT5 in a competitive manner with K_i values of 4.4 μM and 3.2 μM, respectively^[1][2][3].

DL-TBOA ammonium (70-350 μM; 48 hours) treatment concentration-dependently enhances SN38-induced loss of viability. DL-TBOA reversed Oxaliplatin-induced loss of viability^[4].
DL-TBOA ammonium (350 μM; 24 hours) decreases p53 induction by SN38 and oxaliplatin^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DL-TBOA ammonium (10 nmol; i.c.v.) to morphine-dependent rats significantly facilitates the expression of naloxone-precipitated somatic signs and conditioned place aversion^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

256.26

C₁₁H₁₆N₂O₅

2093503-71-8

OC([C@@H](N)[C@@H](C(O)=O)OCC1=CC=CC=C1)=O.N

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shimamoto K, et al. DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201.  [Content Brief]

  [2]. Jabaudon D, et al. Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8733-8.  [Content Brief]

  [3]. Shigeri Y, et al. Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J Neurochem. 2001 Oct;79(2):297-302.  [Content Brief]

  [4]. Pedraz-Cuesta E, et al. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells. BMC Cancer. 2015 May 16;15:411.  [Content Brief]

  [5]. Yumiko Sekiya, et al. Facilitation of morphine withdrawal symptoms and morphine-induced conditioned place preference by a glutamate transporter inhibitor DL-threo-beta-benzyloxyaspartate in rats. Eur J Pharmacol. 2004 Feb 6;485(1-3):201-10.  [Content Brief]